Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial)
Michele Orditura(University of Campania "Luigi Vanvitelli"), Fortunato Ciardiello(University of Campania "Luigi Vanvitelli"), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Vincenzo Montesarchio(CTO Hospital), Eva Lieto(University of Naples Federico II), Guido Giordano(University of Foggia), Raffaele Nettuno(Diocese of Brooklyn), Geppino Genua, Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppe Grimaldi(Policlinico Umberto I), Roberto Mabilia(Ospedale Sant'Anna), Enrico Barbato(Azienda Ospedaliera S.Giuseppe Moscati), Anna Diana(University of Campania "Luigi Vanvitelli"), Alessio Fabozzi(Istituto Oncologico Veneto), Agata Pisano(University of Campania "Luigi Vanvitelli"), Giovanni Iodice(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), E Procaccini(University of Campania "Luigi Vanvitelli"), L. Leopaldi(Ospedale S.Gennaro), Antonio Febbraro(Fatebenefratelli Hospital), Carmela Mocerino(Ospedale Antonio Cardarelli), Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Adriano Gravina(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Luisa Barzelloni(Azienda Ospedaliera S.Giuseppe Moscati), Pasquale Incoronato
Cited by 13
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k